Skip Navigation
Skip to contents

J Pathol Transl Med : Journal of Pathology and Translational Medicine

OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
51 "Joungho Han"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Case Studies
A Rare Case of Adenosquamous Carcinoma Arising in the Background of IgG4-Related Lung Disease
Sangjoon Choi, Sujin Park, Man Pyo Chung, Tae Sung Kim, Jong Ho Cho, Joungho Han
J Pathol Transl Med. 2019;53(3):188-191.   Published online March 11, 2019
DOI: https://doi.org/10.4132/jptm.2019.02.21
  • 5,381 View
  • 154 Download
  • 10 Web of Science
  • 9 Crossref
AbstractAbstract PDF
IgG4-related disease is a systemic inflammatory disease and is known as IgG4-related lung disease (IgG4-RLD) when it involves the respiratory system. Primary lung cancer arising from a background of IgG4-RLD is very rare. Herein, we report a case of adenosquamous carcinoma arising from the background of IgG4-RLD and presenting as an interstitial lung disease pattern. A 66-year-old man underwent lobectomy under the impression of primary lung cancer. Grossly, the mass was ill-defined and gray-tan colored, and the background lung was fibrotic. Microscopically, tumor cells showed both squamous and glandular differentiation. Dense lymphoplasmacytic infiltration with fibrosis and obliterative phlebitis were seen in the background lung. IgG4 immunohistochemical stain showed diffuse positivity in infiltrating plasma cells. Primary lung adenosquamous carcinoma has not been reported in a background of IgG4-RLD. Due to the rarity of IgG4-RLD, physicians must follow patients with IgG4-RLD over long periods of time to accurately predict the risk of lung cancer.

Citations

Citations to this article as recorded by  
  • Endometrioid Carcinomas of the Ovaries and Endometrium Involving Endocervical Polyps: Comprehensive Clinicopathological Analyses
    Jihee Sohn, Yurimi Lee, Hyun-Soo Kim
    Diagnostics.2022; 12(10): 2339.     CrossRef
  • A Case of IgG4-related Disease Composed of a Paravertebral Tumor Alone with Multiple Lung Cancers
    Mutsumi Ozasa, Toyomitsu Sawai, Yosuke Harada, Sumako Yoshioka, Nobuko Matsuo, Hiroshi Mukae
    Haigan.2021; 61(3): 213.     CrossRef
  • Serous Carcinoma of the Endometrium with Mesonephric-Like Differentiation Initially Misdiagnosed as Uterine Mesonephric-Like Adenocarcinoma: A Case Report with Emphasis on the Immunostaining and the Identification of Splice Site TP53 Mutation
    Sangjoon Choi, Yoon Yang Jung, Hyun-Soo Kim
    Diagnostics.2021; 11(4): 717.     CrossRef
  • A Case of IgG4-related Thyroiditis Diagnosed by Total Thyroidectomy
    Daiki Sakamoto, Masao Yagi, Hiroshi Iwai
    Practica Oto-Rhino-Laryngologica.2021; 114(7): 547.     CrossRef
  • Mesonephric-like Differentiation of Endometrial Endometrioid Carcinoma: Clinicopathological and Molecular Characteristics Distinct from Those of Uterine Mesonephric-like Adenocarcinoma
    Sujin Park, Go Eun Bae, Jiyoung Kim, Hyun-Soo Kim
    Diagnostics.2021; 11(8): 1450.     CrossRef
  • Mesonephric-like Adenocarcinoma of the Uterine Corpus: Comprehensive Immunohistochemical Analyses Using Markers for Mesonephric, Endometrioid and Serous Tumors
    Hyunjin Kim, Kiyong Na, Go Eun Bae, Hyun-Soo Kim
    Diagnostics.2021; 11(11): 2042.     CrossRef
  • Not Cancer After All: Two Rare Cases of IgG4-Related Lung Disease
    Josué Pinto, Carla Damas, António Morais
    Archivos de Bronconeumología.2020; 56(1): 53.     CrossRef
  • Not Cancer After All: Two Rare Cases of IgG4-Related Lung Disease
    Josuèc) Pinto, Carla Damas, António Morais
    Archivos de Bronconeumología (English Edition).2020; 56(1): 52.     CrossRef
  • Axillary lymphadenopathy with IgG4 positive plasma cell infiltration as differential diagnosis of metastatic lung adenocarcinoma
    Yutaro Ito, Masanori Harada, Namio Kagoo, Tsutomu Kubota, Koshiro Ichijyo, Eisuke Mochizuki, Masahiro Uehara, Shun Matsuura, Masaru Tsukui, Naoki Koshimizu
    Respiratory Medicine Case Reports.2020; 31: 101196.     CrossRef
Abrupt Dyskeratotic and Squamoid Cells in Poorly Differentiated Carcinoma: Case Study of Two Thoracic NUT Midline Carcinomas with Cytohistologic Correlation
Taebum Lee, Sangjoon Choi, Joungho Han, Yoon-La Choi, Kyungjong Lee
J Pathol Transl Med. 2018;52(5):349-353.   Published online July 27, 2018
DOI: https://doi.org/10.4132/jptm.2018.07.16
  • 7,411 View
  • 138 Download
  • 12 Web of Science
  • 12 Crossref
AbstractAbstract PDF
Cytologic diagnosis of nuclear protein in testis (NUT) midline carcinoma (NMC) is important due to its aggressive behavior and miserable prognosis. Early diagnosis of NMC can facilitate proper management, and here we report two rare cases of thoracic NMC with cytohistologic correlation. In aspiration cytology, the tumor presented with mixed cohesive clusters and dispersed single cells, diffuse background necrosis and many neutrophils. Most of the tumor cells had scanty cytoplasm and medium-sized irregular nuclei, which had fine to granular nuclear chromatin. Interestingly, a few dyskeratotic cells or squamoid cell clusters were present in each case. Biopsy specimen histology revealed more frequent squamous differentiation, and additional immunohistochemistry tests showed nuclear expression of NUT. Because this tumor has a notorious progression and has been previously underestimated in terms of its prevalence, awareness of characteristic findings and proper ancillary tests should be considered in all suspicious cases.

Citations

Citations to this article as recorded by  
  • Diagnostic significance and cytological features of NUT carcinoma by EBUS‐FNA, a case report and literature review
    Yaping Ju, Miriam Velazquez, Andy Sherrod, Tiannan Wang
    Cytopathology.2024;[Epub]     CrossRef
  • BRD3‐NUTM1‐expressing NUT carcinoma of lung on endobronchial ultrasound‐guided transbronchial needle aspiration cytology, a diagnostic pitfall
    Sameer Chhetri Aryal, Shereen Zia, Shannon Rodgers, Yulei Shen, Kyle Perry, Lisi Yuan
    Diagnostic Cytopathology.2022;[Epub]     CrossRef
  • Nuclear protein of the testis midline carcinoma of the thorax
    Ayae Saiki, Keita Sakamoto, Yuan Bee, Takehiro Izumo
    Japanese Journal of Clinical Oncology.2022; 52(6): 531.     CrossRef
  • Approach to Mediastinal Fine Needle Aspiration Cytology
    Zaibo Li, Huihong Xu, Fang Fan
    Advances in Anatomic Pathology.2022; 29(6): 337.     CrossRef
  • Diagnosis, Treatment and Prognosis of Primary Pulmonary NUT Carcinoma: A Literature Review
    Jiaqian Yuan, Zhili Xu, Yong Guo
    Current Oncology.2022; 29(10): 6807.     CrossRef
  • Case report: Immunovirotherapy as a novel add-on treatment in a patient with thoracic NUT carcinoma
    Linus D. Kloker, Branko Calukovic, Katrin Benzler, Alexander Golf, Sebastian Böhm, Sven Günther, Marius Horger, Simone Haas, Susanne Berchtold, Julia Beil, Mary E. Carter, Tina Ganzenmueller, Stephan Singer, Abbas Agaimy, Robert Stöhr, Arndt Hartmann, Tho
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Cytomorphology of primary pulmonary NUT carcinoma in different cytology preparations
    Rimlee Dutta, Aruna Nambirajan, Saurabh Mittal, Sinchita Roy‐Chowdhuri, Deepali Jain
    Cancer Cytopathology.2021; 129(1): 53.     CrossRef
  • Update on genetically defined lung neoplasms: NUT carcinoma and thoracic SMARCA4-deficient undifferentiated tumors
    Kyriakos Chatzopoulos, Jennifer M. Boland
    Virchows Archiv.2021; 478(1): 21.     CrossRef
  • Immunotherapy and Targeting the Tumor Microenvironment: Current Place and New Insights in Primary Pulmonary NUT Carcinoma
    Xiang Li, Hui Shi, Wei Zhang, Chong Bai, Miaoxia He, Na Ta, Haidong Huang, Yunye Ning, Chen Fang, Hao Qin, Yuchao Dong
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Prevalence of NUT carcinoma in head and neck: Analysis of 362 cases with literature review
    Taebum Lee, Junhun Cho, Chung‐Hwan Baek, Young‐Ik Son, Han‐Sin Jeong, Man Ki Chung, Sang Duk Hong, Yong Chan Ahn, Dong Ryul Oh, Jae Myoung Noh, Keunchil Park, Myung‐Ju Ahn, Hyung‐Jin Kim, Yi Kyung Kim, Young Hyeh Ko
    Head & Neck.2020; 42(5): 924.     CrossRef
  • Lung nuclear protein in testis carcinoma in an elderly Korean woman: A case report with cytohistological analysis
    Hwa Jin Cho, Hyun‐Kyung Lee
    Thoracic Cancer.2020; 11(6): 1724.     CrossRef
  • Clinicopathological characteristics of primary lung nuclear protein in testis carcinoma: A single‐institute experience of 10 cases
    Yoon Ah Cho, Yoon‐La Choi, Inwoo Hwang, Kyungjong Lee, Jong Ho Cho, Joungho Han
    Thoracic Cancer.2020; 11(11): 3205.     CrossRef
Original Article
Pulmonary Nodular Lymphoid Hyperplasia with Mass-Formation: Clinicopathologic Characteristics of Nine Cases and Review of the Literature
Jongmin Sim, Hyun Hee Koh, Sangjoon Choi, Jinah Chu, Tae Sung Kim, Hojoong Kim, Joungho Han
J Pathol Transl Med. 2018;52(4):211-218.   Published online June 15, 2018
DOI: https://doi.org/10.4132/jptm.2018.04.27
  • 8,628 View
  • 293 Download
  • 7 Web of Science
  • 7 Crossref
AbstractAbstract PDF
Background
Pulmonary nodular lymphoid hyperplasia (PNLH) is a non-neoplastic pulmonary lymphoid disorder that can be mistaken for malignancy on radiography. Herein, we present nine cases of PNLH, emphasizing clinicoradiological findings and histological features.
Methods
We analyzed radiological and clinicopathological features from the electronic medical records of nine patients (eight females and one male) diagnosed with PNLH. IgG and IgG4 immunohistochemical staining was performed in three patients.
Results
Two of the nine patients had experienced tuberculosis 40 and 30 years prior, respectively. Interestingly, none were current smokers, although two were ex-smokers. Three patients complaining of persistent cough underwent computed tomography of the chest. PNLH was incidentally discovered in five patients during examination for other reasons. The remaining patient was diagnosed with the disease following treatment for pneumonia. Imaging studies revealed consolidation or a mass-like lesion in eight patients. First impressions included invasive adenocarcinoma and mucosal-associated lymphoid tissue‒type lymphoma. Aspergillosis was suspected in the remaining patient based on radiological images. Resection was performed in all patients. Microscopically, the lesions consisted of nodular proliferation of reactive germinal centers accompanied by infiltration of neutrophils and macrophages in various degrees and surrounding fibrosis. Ultimately, all nine patients were diagnosed with PNLH and showed no evidence of recurrence on follow-up.
Conclusions
PNLH is an uncommon but distinct entity with a benign nature, and understanding the radiological and clinicopathological characteristics of PNLH is important.

Citations

Citations to this article as recorded by  
  • Pulmonary Nodular Lymphoid Hyperplasia Evaluated with Bronchoalveolar Lavage Fluid Findings: A Case Report and Review of the Literature on Japanese Patients
    Sakiko Moriyama, Takashi Kido, Noriho Sakamoto, Mai Fuchigami, Takatomo Tokito, Daisuke Okuno, Takuto Miyamura, Shota Nakashima, Atsuko Hara, Hiroshi Ishimoto, Yoshitaka Imaizumi, Kazuto Tsuruda, Katsunori Yanagihara, Junya Fukuoka, Hiroshi Mukae
    Internal Medicine.2023; 62(1): 95.     CrossRef
  • A Case of Pulmonary Nodular Lymphoid Hyperplasia Responding to Corticosteroid Treatment
    Jonathan Teow Koon Goh, Issam Al Jajeh, Jessica Han Ying Tan
    Cureus.2023;[Epub]     CrossRef
  • Pulmonary nodular lymphoid hyperplasia presenting as cavitating lung mass
    Aqeel Alameer, Chary Duraikannu, Avinash Kumar Kanodia, David Dorward
    BMJ Case Reports.2023; 16(8): e254121.     CrossRef
  • Clinicopathological Characteristics and Curative Effect of Lymphoma Based on Sampling Theory
    Shuxiang Ding, Leipo Liu
    Mathematical Problems in Engineering.2022; 2022: 1.     CrossRef
  • Pulmonary nodular lymphoid hyperplasia presenting as multifocal subsolid nodules: A case report and literature review
    Yoon Jin Cha, Duk Hwan Moon, Ji Hyun Park, Sungsoo Lee, Ji Ae Choi, Tae Hoon Kim, Chul Hwan Park
    Respiratory Medicine Case Reports.2022; 36: 101581.     CrossRef
  • Pulmonary nodular lymphoid hyperplasia in a 53-year-old man with malignant sign: a case report
    Zhen Yang, Lianshuang Wei, Xu Li, Xin Liu
    Journal of Cardiothoracic Surgery.2021;[Epub]     CrossRef
  • The diagnostic challenge of adenocarcinoma in pulmonary nodular lymphoid hyperplasia
    Anita Savić Vuković, Melita Kukuljan, Morana Dinter, Ksenija Jurinović, Nives Jonjić
    SAGE Open Medical Case Reports.2021; 9: 2050313X2110393.     CrossRef
Case Study
Cytologic Characteristics of Thymic Adenocarcinoma with Enteric Differentiation: A Study of Four Fine-Needle Aspiration Specimens
Ah-Young Kwon, Joungho Han, Hae-yon Cho, Seokhwi Kim, Heejin Bang, Jiyeon Hyeon
J Pathol Transl Med. 2017;51(5):509-512.   Published online August 4, 2017
DOI: https://doi.org/10.4132/jptm.2017.03.22
  • 6,367 View
  • 109 Download
  • 5 Web of Science
  • 7 Crossref
AbstractAbstract PDF
Thymic adenocarcinoma is extremely rare. Although its histologic features have been occasionally reported, a lack of description of the cytologic features has hampered the prompt and accurate diagnosis of this condition. Herein, we describe the cytologic findings and histology of four aspiration cytology specimens of thymic adenocarcinoma. The specimens were obtained from primary tumors, metastatic lymph nodes, and pericardial effusions. All four specimens showed three-dimensional glandular clusters with a loss of polarity and nuclear overlapping. One specimen had extensive extracellular mucinous material. Three specimens contained tumor cells with intracytoplasmic vacuoles. While the specimen with extracellular mucin showed relatively mild cytologic atypia, other specimens exhibited more atypical cytologic changes: irregular nuclear membranes, a coarse chromatin pattern, and prominent nucleoli. The cytologic features were correlated with the histologic features in each case of enteric type thymic adenocarcinoma. The differential diagnosis included other thymic carcinomas, yolk sac tumors, and metastatic adenocarcinoma from the lung or colorectum.

Citations

Citations to this article as recorded by  
  • Case report: Primary adenocarcinoma NOS of the thymus and cytological features
    Jonathan Willner, Osvaldo Hernandez, Lea Azour, Andre L. Moreira
    Diagnostic Cytopathology.2023;[Epub]     CrossRef
  • Systemic chemotherapy for unresectable or recurrent primary thymic adenocarcinoma of enteric type
    Xiaofang Gao
    International Cancer Conference Journal.2022; 12(1): 46.     CrossRef
  • Thymic adenocarcinoma accompanied by type A thymoma and pulmonary minimally invasive adenocarcinoma and harboring distinct gene alterations
    Yi-Wen Zheng, Lin-Lin Bai, Gui-Yang Jiang, Xu-Yong Lin, Yang Liu, Hong-Tao Xu
    Medicine.2021; 100(15): e25254.     CrossRef
  • A case report: primary thymic adenocarcinoma with enteric differentiation
    Yuuki Kou, Hirokazu Tanaka, Nobuhisa Yamazaki, Hiroyoshi Watanabe, Makoto Sonobe
    The Journal of the Japanese Association for Chest Surgery.2020; 34(2): 107.     CrossRef
  • Primary thymic adenocarcinoma with an aggressive clinical course: An autopsy case showing signet ring cell‐like features
    Ayako Shiono, Takashi Fujino, Kyoichi Kaira, Tomomi Kato, Masanori Yasuda, Kunihiko Kobayashi, Hiroshi Kagamu
    Thoracic Cancer.2020; 11(12): 3609.     CrossRef
  • Primary Thymic Signet Ring Cell Adenocarcinoma: A Currently Unrecognized Variant
    Richard Benedict Supan Roxas, Marie Christine Fajatin Bernardo, Araceli Pacis Jacoba, Janet Lim-Dy, Anarose Cariaga Alvarado, Jasna Metovic, Laura Annaratone, Mauro Papotti
    International Journal of Surgical Pathology.2019; 27(3): 315.     CrossRef
  • Disseminated and massive tumor burden in a case of primary thymic mucinous adenocarcinoma
    Hui-Wen Liu, Chih-Yi Liu, Yi-Chen Yeh
    Journal of Cancer Research and Practice.2019; 6(3): 151.     CrossRef
Brief Case Report
Metastatic Squamous Cell Carcinoma from Lung Adenocarcinoma after Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy
Hyung Kyu Park, Youjeong Seo, Yoon-La Choi, Myung-Ju Ahn, Joungho Han
J Pathol Transl Med. 2017;51(4):441-443.   Published online April 4, 2017
DOI: https://doi.org/10.4132/jptm.2016.10.18
  • 6,219 View
  • 130 Download
  • 8 Web of Science
  • 9 Crossref
PDF

Citations

Citations to this article as recorded by  
  • Spontaneous histological transformation of lung squamous-cell carcinoma to large cell neuroendocrine carcinoma and small cell lung cancer
    Jin-Dong Li, Cheng-Yan Jin, Yan Zhang, Hang Guo, Guang-Lei Zhang, Chun-Guang Wang
    Journal of Cancer Research and Clinical Oncology.2023; 149(13): 11333.     CrossRef
  • Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer
    Fiorella Calabrese, Federica Pezzuto, Francesca Lunardi, Francesco Fortarezza, Sofia-Eleni Tzorakoleftheraki, Maria Vittoria Resi, Mariaenrica Tiné, Giulia Pasello, Paul Hofman
    International Journal of Molecular Sciences.2022; 23(8): 4164.     CrossRef
  • T790M mutation positive squamous cell carcinoma transformation from EGFR-mutated lung adenocarcinoma after low dose erlotinib: A case report and literature review
    Yusaku Kusaba, Yuichiro Takeda, Sakurako Abe, Akinari Tsukada, Go Naka
    Medicine.2022; 101(32): e29682.     CrossRef
  • Case Report: EGFR-Positive Early-Stage Lung Adenocarcinoma Transforming to Squamous Cell Carcinoma After TKI Treatment
    Jiatao Liao, Yuan Li, Chang Liu, Qianqian Long, Jialei Wang
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Squamous cell carcinoma transformation of lung adenocarcinoma after tyrosine kinase inhibitor therapy: Cytological approach
    Alexandra Grosse, Claudia Grosse
    Cytopathology.2020; 31(3): 232.     CrossRef
  • Outcome of EGFR-mutated adenocarcinoma NSCLC patients with changed phenotype to squamous cell carcinoma after tyrosine kinase inhibitors: A pooled analysis with an additional case
    Elisa Roca, Marta Pozzari, William Vermi, Valeria Tovazzi, Alice Baggi, Vito Amoroso, Daniela Nonnis, Salvatore Intagliata, Alfredo Berruti
    Lung Cancer.2019; 127: 12.     CrossRef
  • Squamous Cell Transformation of Primary Lung Adenocarcinoma in a Patient With EML4-ALK Fusion Variant 5 Refractory to ALK Inhibitors
    Jay Gong, Jeffrey P. Gregg, Weijie Ma, Ken Yoneda, Elizabeth H. Moore, Megan E. Daly, Yanhong Zhang, Melissa J. Williams, Tianhong Li
    Journal of the National Comprehensive Cancer Network.2019; 17(4): 297.     CrossRef
  • Pathological transition as the arising mechanism for drug resistance in lung cancer
    Yueqing Chen, Waiying Yvonne Tang, Xinyuan Tong, Hongbin Ji
    Cancer Communications.2019; 39(1): 1.     CrossRef
  • Afatinib

    Reactions Weekly.2017; 1669(1): 18.     CrossRef
Original Articles
Size of Non-lepidic Invasive Pattern Predicts Recurrence in Pulmonary Mucinous Adenocarcinoma: Morphologic Analysis of 188 Resected Cases with Reappraisal of Invasion Criteria
Soohyun Hwang, Joungho Han, Misun Choi, Myung-Ju Ahn, Yong Soo Choi
J Pathol Transl Med. 2017;51(1):56-68.   Published online October 16, 2016
DOI: https://doi.org/10.4132/jptm.2016.09.17
  • 9,045 View
  • 212 Download
  • 8 Web of Science
  • 7 Crossref
AbstractAbstract PDF
Background
We reviewed a series of 188 resected pulmonary mucinous adenocarcinomas (MAs) to clarify the prognostic significance of lepidic and non-lepidic patterns.
Methods
Non-lepidic patterns were divided into bland, non-distorted acini with uncertain invasiveness (pattern 1), unequivocal invasion into stroma (pattern 2), or invasion into alveolar spaces (pattern 3).
Results
The mean proportion of invasive patterns (patterns 2 and 3) was lowest in small (≤ 3 cm) tumors, and gradually increased in intermediate (> 3 cm and ≤ 7 cm) and large (> 7 cm) tumors (8.4%, 34.3%, and 50.1%, respectively). Adjusted T (aT) stage, as determined by the size of invasive patterns, was positively correlated with adverse histologic and clinical features including older age, male sex, and ever smokers. aTis tumors, which were exclusively composed of lepidic pattern (n = 9), or a mixture of lepidic and pattern 1 (n = 40) without any invasive patterns, showed 100% disease- free survival (DFS). The aT1mi tumors, with minimal (≤ 5 mm) invasive patterns (n = 63), showed a 95.2% 5-year DFS, with recurrences (n = 2) limited to tumors greater than 3 cm in total size (n = 23). Both T and aT stage were significantly associated with DFS; however, survival within the separate T-stage subgroups was stratified according to the aT stage, most notably in the intermediatestage subgroups. In multivariate analysis, the size of invasive patterns (p = .020), pleural invasion (p < .001), and vascular invasion (p = .048) were independent predictors of recurrence, whereas total size failed to achieve statistical significance (p = .121).
Conclusions
This study provides a rationale for histologic risk stratification in pulmonary MA based on the extent of invasive growth patterns with refined criteria for invasion.

Citations

Citations to this article as recorded by  
  • Distinct Recurrence Pattern and Survival Outcomes of Invasive Mucinous Adenocarcinoma of the Lung: The Potential Role of Local Therapy in Intrapulmonary Spread
    Dong Woog Yoon, Soohyun Hwang, Tae Hee Hong, Yoon-La Choi, Hong Kwan Kim, Yong Soo Choi, Jhingook Kim, Young Mog Shim, Jong Ho Cho
    Annals of Surgical Oncology.2024; 31(1): 201.     CrossRef
  • Pulmonary invasive mucinous adenocarcinoma
    Wei‐Chin Chang, Yu Zhi Zhang, Andrew G Nicholson
    Histopathology.2024; 84(1): 18.     CrossRef
  • Micropapillary Pattern in Invasive Mucinous Adenocarcinoma of the Lung: Comparison With Invasive Non-Mucinous Adenocarcinoma
    Hui He, Lue Li, Yuan-yuan Wen, Li-yong Qian, Zhi-qiang Yang
    International Journal of Surgical Pathology.2023;[Epub]     CrossRef
  • Radiological and clinical features of screening-detected pulmonary invasive mucinous adenocarcinoma
    Dae Hyeon Kim, So Young Bae, Kwon Joong Na, Samina Park, In Kyu Park, Chang Hyun Kang, Young Tae Kim
    Interactive CardioVascular and Thoracic Surgery.2022; 34(2): 229.     CrossRef
  • Micropapillary Pattern in Invasive Mucinous Adenocarcinoma of the Lung: Comparison with Invasive Non-Mucinous Adenocarcinoma
    Hui He, Yuanyuan Wen, Liyong Qian, Zhiqiang Yang
    SSRN Electronic Journal .2022;[Epub]     CrossRef
  • Optimal method for measuring invasive size that predicts survival in invasive mucinous adenocarcinoma of the lung
    Tomonari Oki, Keiju Aokage, Shogo Nomura, Kenta Tane, Tomohiro Miyoshi, Norihiko Shiiya, Kazuhito Funai, Masahiro Tsuboi, Genichiro Ishii
    Journal of Cancer Research and Clinical Oncology.2020; 146(5): 1291.     CrossRef
  • Prognostic Impact of Histopathologic Features in Pulmonary Invasive Mucinous Adenocarcinomas
    Wei-Chin Chang, Yu Zhi Zhang, Eric Lim, Andrew G Nicholson
    American Journal of Clinical Pathology.2020; 154(1): 88.     CrossRef
Transformation to Small Cell Lung Cancer of Pulmonary Adenocarcinoma: Clinicopathologic Analysis of Six Cases
Soomin Ahn, Soo Hyun Hwang, Joungho Han, Yoon-La Choi, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn, Woong-Yang Park
J Pathol Transl Med. 2016;50(4):258-263.   Published online May 10, 2016
DOI: https://doi.org/10.4132/jptm.2016.04.19
  • 10,643 View
  • 235 Download
  • 44 Web of Science
  • 40 Crossref
AbstractAbstract PDF
Background
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are considered the first line treatment for a subset of EGFR-mutated non-small cell lung cancer (NSCLC) patients. Although transformation to small cell lung cancer (SCLC) is one of the known mechanisms of resistance to EGFR TKIs, it is not certain whether transformation to SCLC is exclusively found as a mechanism of TKI resistance in EGFR-mutant tumors.
Methods
We identified six patients with primary lung adenocarcinoma that showed transformation to SCLC on second biopsy (n = 401) during a 6-year period. Clinicopathologic information was analyzed and EGFR mutation results were compared between initial and second biopsy samples.
Results
Six patients showed transformation from adenocarcinoma to SCLC, of which four were pure SCLCs and two were combined adenocarcinoma and SCLCs. Clinically, four cases were EGFR-mutant tumors from non-smoking females who underwent TKI treatment, and the EGFR mutation was retained in the transformed SCLC tumors. The remaining two adenocarcinomas were EGFR wild-type, and one of these patients received EGFR TKI treatment.
Conclusions
NSCLC can acquire a neuroendocrine phenotype with or without EGFR TKI treatment.

Citations

Citations to this article as recorded by  
  • Transformation to small cell lung cancer is irrespective of EGFR and accelerated by SMAD4-mediated ASCL1 transcription independently of RB1 in non-small cell lung cancer
    Xi Ding, Min-xing Shi, Di Liu, Jing-xue Cao, Kai-xuan Zhang, Run-dong Zhang, Li-ping Zhang, Kai-xing Ai, Bo Su, Jie Zhang
    Cell Communication and Signaling.2024;[Epub]     CrossRef
  • The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies
    Alessandra Ferro, Gian Marco Marinato, Cristiana Mulargiu, Monica Marino, Giulia Pasello, Valentina Guarneri, Laura Bonanno
    Critical Reviews in Oncology/Hematology.2024; 196: 104295.     CrossRef
  • Comprehensive molecular and clinical insights into non-small cell lung cancer transformation to small cell lung cancer with an illustrative case report
    Kresimir Tomic, Kristina Krpina, Lara Baticic, Miroslav Samarzija, Semir Vranic
    Journal of Drug Targeting.2024; : 1.     CrossRef
  • Exon-18-EGFR Mutated Transformed Small-Cell Lung Cancer: A Case Report and Literature Review
    Nunzio Digiacomo, Tommaso De Pas, Giovanna Rossi, Paola Bossi, Erika Stucchi, Fabio Conforti, Emilia Cocorocchio, Daniele Laszlo, Laura Pala, Emma Zattarin, Chiara Catania
    Current Oncology.2023; 30(3): 3494.     CrossRef
  • Current knowledge of small cell lung cancer transformation from non-small cell lung cancer
    Giuseppe Giaccone, Yongfeng He
    Seminars in Cancer Biology.2023; 94: 1.     CrossRef
  • Targeting the EGFR signaling pathway in cancer therapy: What’s new in 2023?
    Sushanta Halder, Soumi Basu, Shobhit P. Lall, Apar K. Ganti, Surinder K. Batra, Parthasarathy Seshacharyulu
    Expert Opinion on Therapeutic Targets.2023; 27(4-5): 305.     CrossRef
  • Outcomes in Patients With Lung Adenocarcinoma With Transformation to Small Cell Lung Cancer After EGFR Tyrosine Kinase Inhibitors Resistance: A Systematic Review and Pooled Analysis
    Jinhe Xu, Lihuan Xu, Baoshan Wang, Wencui Kong, Ying Chen, Zongyang Yu
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Small cell lung cancer transformation: From pathogenesis to treatment
    Xiaomeng Yin, Yueyi Li, Hang Wang, Tingting Jia, Enli Wang, Yuling Luo, Yuhao Wei, Zeyi Qin, Xuelei Ma
    Seminars in Cancer Biology.2022; 86: 595.     CrossRef
  • Small Cell Lung Cancer Transformation following Treatment in EGFR-Mutated Non-Small Cell Lung Cancer
    Isa Mambetsariev, Leonidas Arvanitis, Jeremy Fricke, Rebecca Pharaon, Angel R. Baroz, Michelle Afkhami, Marianna Koczywas, Erminia Massarelli, Ravi Salgia
    Journal of Clinical Medicine.2022; 11(5): 1429.     CrossRef
  • Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer
    Fiorella Calabrese, Federica Pezzuto, Francesca Lunardi, Francesco Fortarezza, Sofia-Eleni Tzorakoleftheraki, Maria Vittoria Resi, Mariaenrica Tiné, Giulia Pasello, Paul Hofman
    International Journal of Molecular Sciences.2022; 23(8): 4164.     CrossRef
  • Genomic and Gene Expression Studies Helped to Define the Heterogeneity of Small-Cell Lung Cancer and Other Lung Neuroendocrine Tumors and to Identify New Therapeutic Targets
    Ugo Testa, Elvira Pelosi, Germana Castelli
    Onco.2022; 2(3): 186.     CrossRef
  • Neuroendocrine transformation from EGFR/ALK-wild type or TKI-naïve non-small cell lung cancer: An under-recognized phenomenon
    Xiao Chu, Yuyin Xu, Ye Li, Yue Zhou, Li Chu, Xi Yang, Jianjiao Ni, Yida Li, Tiantian Guo, Zhiqin Zheng, Qiang Zheng, Qianlan Yao, Yuan Li, Xiaoyan Zhou, Zhengfei Zhu
    Lung Cancer.2022; 169: 22.     CrossRef
  • Three Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Similarities and Differences
    Ling Chen, Yangqingqing Zhou, Chaosheng Gan, XiaoLi Wang, Yihui Liu, Chunhui Dong, Ruiyuan He, Jin Yang
    Cancer Investigation.2022; 40(7): 590.     CrossRef
  • Histomorphological transformation from non-small cell lung carcinoma to small cell lung carcinoma after targeted therapy or immunotherapy: A report of two cases
    Hao Liu, Li-Hong Chen, Zhi-Hui Zhang, Ning Wang, Si-Hui Zhuang, Hao Chen, Jin Du, Li-Juan Pang, Yan Qi
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient
    Maurício Fernando Silva Almeida Ribeiro, Franciele Hinterholz Knebel, Fabiana Bettoni, Rodrigo Saddi, Karina Perez Sacardo, Felipe Sales Nogueira Amorim Canedo, João Victor Machado Alessi, Andrea Kazumi Shimada, José Flávio Gomes Marin, Anamaria Aranha Ca
    npj Precision Oncology.2021;[Epub]     CrossRef
  • Histological transformation of non-small cell lung cancer: Clinical analysis of nine cases
    Cai-Bao Jin, Ling Yang
    World Journal of Clinical Cases.2021; 9(18): 4617.     CrossRef
  • Lamellarin 14, a derivative of marine alkaloids, inhibits the T790M/C797S mutant epidermal growth factor receptor
    Naoyuki Nishiya, Yusuke Oku, Chie Ishikawa, Tsutomu Fukuda, Shingo Dan, Tetsuo Mashima, Masaru Ushijima, Yoko Furukawa, Yuka Sasaki, Keishi Otsu, Tomoko Sakyo, Masanori Abe, Honami Yonezawa, Fumito Ishibashi, Masaaki Matsuura, Akihiro Tomida, Hiroyuki Sei
    Cancer Science.2021; 112(5): 1963.     CrossRef
  • Case Report: Transformation From Non-Small Cell Lung Cancer to Small Cell Lung Cancer During Anti-PD-1 Therapy: A Report of Two Cases
    Qian Shen, Jingjing Qu, Lingyan Sheng, Qiqi Gao, Jianying Zhou
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Exploring the resistance mechanisms of second-line osimertinib and their prognostic implications using next-generation sequencing in patients with non-small-cell lung cancer
    Kyoungmin Lee, Deokhoon Kim, Shinkyo Yoon, Dae Ho Lee, Sang-We Kim
    European Journal of Cancer.2021; 148: 202.     CrossRef
  • Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma
    Shouzheng Wang, Tongji Xie, Xuezhi Hao, Yan Wang, Xingsheng Hu, Lin Wang, Yan Li, Junling Li, Puyuan Xing
    Thoracic Cancer.2021; 12(19): 2585.     CrossRef
  • EGFR-Mutant SCLC Exhibits Heterogeneous Phenotypes and Resistance to Common Antineoplastic Drugs
    Chih-An Lin, Sung-Liang Yu, Hsuan-Yu Chen, Huei-Wen Chen, Shr-Uen Lin, Chia-Ching Chang, Chong-Jen Yu, Pan-Chyr Yang, Chao-Chi Ho
    Journal of Thoracic Oncology.2019; 14(3): 513.     CrossRef
  • The clinicopathologic of pulmonary adenocarcinoma transformation to small cell lung cancer
    Haiyan Yang, Li Liu, Chunhua Zhou, Yi Xiong, Yijuan Hu, Nong Yang, Jingjing Qu
    Medicine.2019; 98(12): e14893.     CrossRef
  • Chemistry and pharmacological diversity of quinoxaline motifs as anticancer agents
    Olayinka O. Ajani, Martins T. Nlebemuo, Joseph A. Adekoya, Kehinde O. Ogunniran, Tolutope O. Siyanbola, Christiana O. Ajanaku
    Acta Pharmaceutica.2019; 69(2): 177.     CrossRef
  • Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives
    Chiara Tomasello, Cinzia Baldessari, Martina Napolitano, Giulia Orsi, Giulia Grizzi, Federica Bertolini, Fausto Barbieri, Stefano Cascinu
    Critical Reviews in Oncology/Hematology.2018; 123: 149.     CrossRef
  • Small cell lung cancer transformation from EGFR-mutated lung adenocarcinoma: A case report and literatures review
    Yangyang Liu
    Cancer Biology & Therapy.2018; 19(6): 445.     CrossRef
  • Anaplastic lymphoma kinase (ALK)-expressing Lung Adenocarcinoma with Combined Neuroendocrine Component or Neuroendocrine Transformation: Implications for Neuroendocrine Transformation and Response to ALK-tyrosine Kinase Inhibitors
    Jongmin Sim, Hyunjin Kim, Jiyeon Hyeon, Yoon-La Choi, Joungho Han
    Journal of Korean Medical Science.2018;[Epub]     CrossRef
  • Assessment of Resistance Mechanisms and Clinical Implications in Patients WithEGFRT790M–Positive Lung Cancer and Acquired Resistance to Osimertinib
    Geoffrey R. Oxnard, Yuebi Hu, Kathryn F. Mileham, Hatim Husain, Daniel B. Costa, Philip Tracy, Nora Feeney, Lynette M. Sholl, Suzanne E. Dahlberg, Amanda J. Redig, David J. Kwiatkowski, Michael S. Rabin, Cloud P. Paweletz, Kenneth S. Thress, Pasi A. Jänne
    JAMA Oncology.2018; 4(11): 1527.     CrossRef
  • Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer
    Mong-Wei Lin, Kang-Yi Su, Te-Jen Su, Chia-Ching Chang, Jing-Wei Lin, Yi-Hsuan Lee, Sung-Liang Yu, Jin-Shing Chen, Min-Shu Hsieh
    Lung Cancer.2018; 125: 282.     CrossRef
  • Transformation to small‑cell lung cancer following treatment with icotinib in a patient with lung adenocarcinoma
    Hongyang Lu, Bo Chen, Jing Qin, Fajun Xie, Na Han, Zhiyu Huang
    Oncology Letters.2018;[Epub]     CrossRef
  • Histological transformation of adenocarcinoma to small cell carcinoma lung as a rare mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors: Report of a case with review of literature
    Monalisa Hui, ShantveerG Uppin, BalaJoseph Stalin, G Sadashivudu
    Lung India.2018; 35(2): 160.     CrossRef
  • A rare case of squamous cell carcinoma lung with multiple locoregional recurrences and histological transformation
    Ram Niwas, Shibdas Chakrabarti, Viswesvaran Balasubramanian, ManasKamal Sen, JagdishChander Suri
    Lung India.2018; 35(6): 511.     CrossRef
  • Small cell lung cancer transformation during immunotherapy with nivolumab: A case report
    Takuma Imakita, Kohei Fujita, Osamu Kanai, Tsuyoshi Terashima, Tadashi Mio
    Respiratory Medicine Case Reports.2017; 21: 52.     CrossRef
  • Pulmonary neuroendocrine tumor in a female wolf (Canis lupus lupus)
    Ayako SHIRAKI, Toshinori YOSHIDA, Masahi KAWASHIMA, Hirotada MURAYAMA, Rei NAGAHARA, Nanao ITO, Makoto SHIBUTANI
    Journal of Veterinary Medical Science.2017; 79(3): 588.     CrossRef
  • Secondary biopsy of non‐oncogenic‐driven lung cancer may reveal a clinically sensible histologic change. A brief report of two paradigmatic cases
    Maria C. Mengoli, Giulia Orsi, Filippo Lococo, Giulia Grizzi, Fausto Barbieri, Federica Bertolini, Giulio Rossi, Silvia Novello
    Thoracic Cancer.2017; 8(4): 359.     CrossRef
  • Small-cell lung cancer in never smokers: The clinicopathological features including the prognosis
    Masahiro Yamasaki, Naomi Saito, Wakako Daido, Sayaka Ishiyama, Naoko Deguchi, Masaya Taniwaki, Akio Sakatani, Megumu Fujihara, Nobuyuki Ohashi, Ken-ichi Arita
    Cancer Treatment and Research Communications.2017; 12: 1.     CrossRef
  • Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas
    June-Koo Lee, Junehawk Lee, Sehui Kim, Soyeon Kim, Jeonghwan Youk, Seongyeol Park, Yohan An, Bhumsuk Keam, Dong-Wan Kim, Dae Seog Heo, Young Tae Kim, Jin-Soo Kim, Se Hyun Kim, Jong Seok Lee, Se-Hoon Lee, Keunchil Park, Ja-Lok Ku, Yoon Kyung Jeon, Doo Hyun
    Journal of Clinical Oncology.2017; 35(26): 3065.     CrossRef
  • Australian recommendations for EGFR T790M testing in advanced non-small cell lung cancer
    Thomas John, Jeffrey J Bowden, Stephen Clarke, Stephen B Fox, Kerryn Garrett, Keith Horwood, Christos S Karapetis
    Asia-Pacific Journal of Clinical Oncology.2017; 13(4): 296.     CrossRef
  • Metastatic Squamous Cell Carcinoma from Lung Adenocarcinoma after Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy
    Hyung Kyu Park, Youjeong Seo, Yoon-La Choi, Myung-Ju Ahn, Joungho Han
    Journal of Pathology and Translational Medicine.2017; 51(4): 441.     CrossRef
  • Sequential occurrence of small cell and non-small lung cancer in a male patient: Is it a transformation?
    Ahsan Wahab, Kavitha Kesari, Siddique Chaudhary, Mahin Khan, Hafiz Khan, Susan Smith, Yanis Boumber
    Cancer Biology & Therapy.2017; 18(12): 940.     CrossRef
  • The expression of S100B protein in serum of patients with brain metastases from small-cell lung cancer and its clinical significance
    Shanling Mu, Hong Ma, Jun Shi, Dezhi Zhen
    Oncology Letters.2017;[Epub]     CrossRef
Case Study
Pulmonary Arteriovenous Fistula: Clinical and Histologic Spectrum of Four Cases
Soomin Ahn, Joungho Han, Hong Kwan Kim, Tae Sung Kim
J Pathol Transl Med. 2016;50(5):390-393.   Published online May 9, 2016
DOI: https://doi.org/10.4132/jptm.2016.04.18
  • 8,642 View
  • 169 Download
  • 6 Web of Science
  • 6 Crossref
AbstractAbstract PDF
Pulmonary arteriovenous fistula (PAVF) is abnormally dilated vessels that provide a right-to-left shunt between pulmonary artery and pulmonary vein and is clinically divided into simple and complex type. Here, we report four cases of surgically resected sporadic PAVFs presenting various clinical and histologic spectrums. Cases 1 (a 57-old-female) and 2 (a 54-old-female) presented as incidentally identified single aneurysmal fistulas and the lesions were surgically removed without complication. On the other hand, case 3 (an 11-old-male) showed diffuse dilated vascular sacs involving both lungs and caused severe hemodynamic and pulmonary dysfunction. Embolization and surgical resection of the main lesion failed to relieve the symptoms. Case 4 (a 36-old-male) had a localized multiloculated cyst clinically mimicking congenital cystic adenomatoid malformation. Microscopically, the lesion consisted of dilated thick vessels, consistent with the diagnosis of fistulous arteriovenous malformation/hemangioma.

Citations

Citations to this article as recorded by  
  • The Shunt of It
    Brittany M. Scarpato, Jamie McDonald, Pinar Bayrak-Toydemir, C. Gregory Elliott, Barbara C. Cahill, Lyska L. Emerson, Lynn M. Keenan
    Chest.2023; 163(5): e201.     CrossRef
  • Pyogenic Brain Abscesses in a Patient With Digital Clubbing
    Vimal Kumar Paliwal, Sucharita Anand, Vivek Singh
    JAMA Neurology.2020; 77(1): 129.     CrossRef
  • Recurrent hemoptysis caused by arteriovenous malformation
    Ivana Meta-Jevtović, Romana Suša, Bojan Đokić
    Medicinski casopis.2020; 54(3): 120.     CrossRef
  • A 10-year-old boy with dyspnea and hypoxia: abernathy malformation masquerading as pulmonary arteriovenous fistula
    Lijian Xie, Yun Li, Xunwei Jiang, Jian Zhao, Tingting Xiao
    BMC Pediatrics.2019;[Epub]     CrossRef
  • Characteristics and analysis of right-to-left shunt-related dizziness in patients without hypoxemia
    Liming Cao
    Journal of International Medical Research.2019; 47(7): 2921.     CrossRef
  • A ruptured pulmonary arteriovenous fistula after laparoscopic operation
    Hong-Wei Shang, Sheng-Bin Sun, Guang-Yao Ma, Xing-Ming Mei, Chao Li, Kang Yang
    Chinese Journal of Traumatology.2017; 20(6): 359.     CrossRef
Original Article
Non-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases
Taebum Lee, Boram Lee, Yoon-La Choi, Joungho Han, Myung-Ju Ahn, Sang-Won Um
J Pathol Transl Med. 2016;50(3):197-203.   Published online April 18, 2016
DOI: https://doi.org/10.4132/jptm.2016.03.09
  • 17,397 View
  • 288 Download
  • 69 Web of Science
  • 61 Crossref
AbstractAbstract PDF
Background
Although epidermal growth factor receptor (EGFR), v-Ki-ras2 Kirsten rat sarcoma viral oncogene (KRAS), and anaplastic lymphoma kinase (ALK) mutations in non-small cell lung cancer (NSCLC) were thought to be mutually exclusive, some tumors harbor concomitant mutations. Discovering a driver mutation on the basis of morphologic features and therapeutic responses with mutation analysis can be used to understand pathogenesis and predict resistance in targeted therapy.
Methods
In 6,637 patients with NSCLC, 12 patients who had concomitant mutations were selected and clinicopathologic features were reviewed. Clinical characteristics included sex, age, smoking history, previous treatment, and targeted therapy with response and disease-free survival. Histologic features included dominant patterns, nuclear and cytoplasmic features.
Results
All patients were diagnosed with adenocarcinoma and had an EGFR mutation. Six patients had concomitant KRAS mutations and the other six had ALK mutations. Five of six EGFR-KRAS mutation patients showed papillary and acinar histologic patterns with hobnail cells. Three of six received EGFR tyrosine kinase inhibitor (TKI) and showed partial response for 7–29 months. All six EGFR-ALK mutation patients showed solid or cribriform patterns and three had signet ring cells. Five of six EGFR-ALK mutation patients received EGFR TKI and/or ALK inhibitor and four showed partial response or stable disease, except for one patient who had acquired an EGFR mutation.
Conclusions
EGFR and ALK mutations play an important role as driver mutations in double mutated NSCLC, and morphologic analysis can be used to predict treatment response.

Citations

Citations to this article as recorded by  
  • Artificial Intelligence in Lung Cancer Imaging: From Data to Therapy
    Michaela Cellina, Giuseppe De Padova, Nazarena Caldarelli, Dario Libri, Maurizio Cè, Carlo Martinenghi, Marco Alì, Sergio Papa, Gianpaolo Carrafiello
    Critical Reviews™ in Oncogenesis.2024; 29(2): 1.     CrossRef
  • Artificial Intelligence for Cardiothoracic Imaging: Overview of Current and Emerging Applications
    Bruno Hochhegger, Romulo Pasini, Alysson Roncally Carvalho, Rosana Rodrigues, Stephan Altmayer, Leonardo Kayat Bittencourt, Edson Marchiori, Reza Forghani
    Seminars in Roentgenology.2023; 58(2): 184.     CrossRef
  • Genomic Landscape of Primary Resistance to Osimertinib Among Hispanic Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Results of an Observational Longitudinal Cohort Study
    Diego F. Chamorro, Andrés F. Cardona, July Rodríguez, Alejandro Ruiz-Patiño, Oscar Arrieta, Darwin A. Moreno-Pérez, Leonardo Rojas, Zyanya Lucia Zatarain-Barrón, Dora V. Ardila, Lucia Viola, Gonzalo Recondo, Juan B. Blaquier, Claudio Martín, Luis Raez, Su
    Targeted Oncology.2023; 18(3): 425.     CrossRef
  • Histone deacetylase inhibitor belinostat regulates metabolic reprogramming in killing KRAS‐mutant human lung cancer cells
    Rebecca M. Peter, Md. Shahid Sarwar, Sarah Z. Mostafa, Yujue Wang, Xiaoyang Su, Ah‐Ng Kong
    Molecular Carcinogenesis.2023; 62(8): 1136.     CrossRef
  • Differential Distribution of Brain Metastases from Non-Small Cell Lung Cancer Based on Mutation Status
    Bihong T. Chen, Taihao Jin, Ningrong Ye, Sean W. Chen, Russell C. Rockne, Stephanie Yoon, Isa Mambetsariev, Ebenezer Daniel, Ravi Salgia
    Brain Sciences.2023; 13(7): 1057.     CrossRef
  • Clinicopathological features and prognostic significance of pulmonary adenocarcinoma with signet ring cell components: meta-analysis and SEER analysis
    Yang Tan, Ying-he Huang, Jia-wen Xue, Rui Zhang, Run Liu, Yan Wang, Zhen-Bo Feng
    Clinical and Experimental Medicine.2023; 23(8): 4341.     CrossRef
  • Ganoderma microsporum immunomodulatory protein as an extracellular epidermal growth factor receptor (EGFR) degrader for suppressing EGFR-positive lung cancer cells
    Wei-Jyun Hua, Hsin Yeh, Zhi-Hu Lin, Ai-Jung Tseng, Li-Chen Huang, Wei-Lun Qiu, Tsung-Hsi Tu, Ding-Han Wang, Wei-Hung Hsu, Wei-Lun Hwang, Tung-Yi Lin
    Cancer Letters.2023; 578: 216458.     CrossRef
  • Next generation sequencing for detection of EGFR alterations in NSCLC: is more better?
    Ullas Batra, Shrinidhi Nathany, Mansi Sharma, Parveen Jain, Anurag Mehta
    Journal of Clinical Pathology.2022; 75(3): 164.     CrossRef
  • Enkurin domain containing 1 (ENKD1) regulates the proliferation, migration and invasion of non‐small cell lung cancer cells
    Ting Song, Peng Zhou, Chunjiao Sun, Na He, Haixia Li, Jie Ran, Jun Zhou, Yue Wu, Min Liu
    Asia-Pacific Journal of Clinical Oncology.2022;[Epub]     CrossRef
  • Targeting Mutant Kirsten Rat Sarcoma Viral Oncogene Homolog in Non-Small Cell Lung Cancer: Current Difficulties, Integrative Treatments and Future Perspectives
    Jia-Xin Li, Run-Ze Li, Lin-Rui Ma, Peng Wang, Dong-Han Xu, Jie Huang, Li-Qi Li, Ling Tang, Ying Xie, Elaine Lai-Han Leung, Pei-Yu Yan
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • Histone H3K9 methyltransferase SETDB1 augments invadopodia formation to promote tumor metastasis
    Shuhei Ueshima, Jia Fang
    Oncogene.2022; 41(24): 3370.     CrossRef
  • ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer
    A. Passaro, N. Leighl, F. Blackhall, S. Popat, K. Kerr, M.J. Ahn, M.E. Arcila, O. Arrieta, D. Planchard, F. de Marinis, A.M. Dingemans, R. Dziadziuszko, C. Faivre-Finn, J. Feldman, E. Felip, G. Curigliano, R. Herbst, P.A. Jänne, T. John, T. Mitsudomi, T.
    Annals of Oncology.2022; 33(5): 466.     CrossRef
  • Molecular Targets in Lung Cancer: Study of the Evolution of Biomarkers Associated with Treatment with Tyrosine Kinase Inhibitors—Has NF1 Tumor Suppressor a Key Role in Acquired Resistance?
    Begoña O. Alen, Lara S. Estévez-Pérez, María Teresa Hermida-Romero, Ana Reguera-Arias, Rosario García-Campelo, Mercedes de la Torre-Bravos, Ángel Concha
    Cancers.2022; 14(14): 3323.     CrossRef
  • Analytical and clinical validation of a custom 15-gene next-generation sequencing panel for the evaluation of circulating tumor DNA mutations in patients with advanced non-small-cell lung cancer
    Yock Ping Chow, Norziha Zainul Abidin, Ken Siong Kow, Lye Mun Tho, Chieh Lee Wong, Rama Krishna Kancha
    PLOS ONE.2022; 17(10): e0276161.     CrossRef
  • Potential Therapeutic Strategy for EGFR-Mutant Lung Cancer With Concomitant EML4-ALK Rearrangement—Combination of EGFR Tyrosine Kinase Inhibitors and ALK Inhibitors
    Ming-Hung Huang, Jih-Hsiang Lee, Pei-Shan Hung, James Chih-Hsin Yang
    JTO Clinical and Research Reports.2022; 3(11): 100405.     CrossRef
  • Artificial Intelligence in Lung Cancer Imaging: Unfolding the Future
    Michaela Cellina, Maurizio Cè, Giovanni Irmici, Velio Ascenti, Natallia Khenkina, Marco Toto-Brocchi, Carlo Martinenghi, Sergio Papa, Gianpaolo Carrafiello
    Diagnostics.2022; 12(11): 2644.     CrossRef
  • A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice
    Yanxia Liu, Yuan Gao, Ying Wang, Cong Zhao, Zhiyun Zhang, Baolan Li, Tongmei Zhang
    BMC Cancer.2022;[Epub]     CrossRef
  • High frequency of KRAS and EGFR mutation profiles in BRAF-negative thyroid carcinomas in Indonesia
    Didik Setyo Heriyanto, Vincent Laiman, Nikko Vanda Limantara, Widyan Putra Anantawikrama, Fara Silvia Yuliani, Rita Cempaka, Sumadi Lukman Anwar
    BMC Research Notes.2022;[Epub]     CrossRef
  • Targeted next-generation sequencing for cancer-associated gene mutation and copy number detection in 206 patients with non–small-cell lung cancer
    Songbai Zheng, Xiaodan Wang, Ying Fu, Beibei Li, Jianhua Xu, Haifang Wang, Zhen Huang, Hui Xu, Yurong Qiu, Yaozhou Shi, Kui Li
    Bioengineered.2021; 12(1): 791.     CrossRef
  • How mathematical modeling could contribute to the quantification of metastatic tumor burden under therapy: insights in immunotherapeutic treatment of non-small cell lung cancer
    Pirmin Schlicke, Christina Kuttler, Christian Schumann
    Theoretical Biology and Medical Modelling.2021;[Epub]     CrossRef
  • A case of concomitant EGFR/ALK alteration against a mutated EGFR background in early-stage lung adenocarcinoma
    Ki-Chang Lee, Jiwon Koh, Doo Hyun Chung, Yoon Kyung Jeon
    Journal of Pathology and Translational Medicine.2021; 55(2): 139.     CrossRef
  • Malfeasance of KRAS mutations in carcinogenesis
    Rupal Tripathi, Shrinidhi Nathany, Anurag Mehta, Ullas Batra, Sakshi Mattoo, Mansi Sharma
    Clinical and Experimental Medicine.2021; 21(3): 439.     CrossRef
  • Detection of Low-Frequency KRAS Mutations in cfDNA From EGFR-Mutated NSCLC Patients After First-Line EGFR Tyrosine Kinase Inhibitors
    Giorgia Nardo, Jessica Carlet, Ludovica Marra, Laura Bonanno, Alice Boscolo, Alessandro Dal Maso, Andrea Boscolo Bragadin, Stefano Indraccolo, Elisabetta Zulato
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Non-Small Cell Lung Cancer Harboring Concurrent EGFR Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma
    Valerio Gristina, Maria La Mantia, Antonio Galvano, Sofia Cutaia, Nadia Barraco, Marta Castiglia, Alessandro Perez, Marco Bono, Federica Iacono, Martina Greco, Katia Calcara, Valentina Calò, Sergio Rizzo, Lorena Incorvaia, Maria Chiara Lisanti, Giulia San
    Journal of Molecular Pathology.2021; 2(2): 173.     CrossRef
  • Testing for EGFR Mutations and ALK Rearrangements in Advanced Non-Small-Cell Lung Cancer: Considerations for Countries in Emerging Markets
    Mercedes L Dalurzo, Alejandro Avilés-Salas, Fernando Augusto Soares, Yingyong Hou, Yuan Li, Anna Stroganova, Büge Öz, Arif Abdillah, Hui Wan, Yoon-La Choi
    OncoTargets and Therapy.2021; Volume 14: 4671.     CrossRef
  • Untangling the KRAS mutated lung cancer subsets and its therapeutic implications
    Kulshrestha Ritu, Pawan Kumar, Amit Singh, K. Nupur, Sonam Spalgias, Parul Mrigpuri, Rajkumar
    Molecular Biomedicine.2021;[Epub]     CrossRef
  • Lorlatinib Induces Durable Disease Stabilization in a Pancreatic Cancer Patient with a ROS1 p.L1950F Mutation: Case Report
    Janna-Lisa Velthaus, Peter Iglauer, Ronald Simon, Carsten Bokemeyer, Peter Bannas, Niklas Beumer, Charles D. Imbusch, Eray Goekkurt, Sonja Loges
    Oncology Research and Treatment.2021; 44(9): 495.     CrossRef
  • Proteasome-dependent degradation of Smad7 is critical for lung cancer metastasis
    Lu Tong, Shihui Shen, Quan Huang, Junjiang Fu, Tianzhen Wang, Linian Pan, Pei Zhang, Geng Chen, Tingmei Huang, Ke Li, Qingwu Liu, Shaofang Xie, Xiao Yang, Robb E. Moses, Xiaotao Li, Lei Li
    Cell Death & Differentiation.2020; 27(6): 1795.     CrossRef
  • Circulating cell-free DNA as a diagnostic and prognostic biomarker for non-small-cell lung cancer: a systematic review and meta-analysis
    Zhoumiao Chen, Huiwen Miao, Qingxin Zeng, Shaohua Xu, Zhao Chen, Kai Liu
    Biomarkers in Medicine.2020; 14(7): 587.     CrossRef
  • Influence of EGFR-activating mutations on sensitivity to tyrosine kinase inhibitors in a KRAS mutant non-small cell lung cancer cell line
    Yoshinori Tsukumo, Mikihiko Naito, Takayoshi Suzuki, Srikumar Chellappan
    PLOS ONE.2020; 15(3): e0229712.     CrossRef
  • KRAS oncogene may be another target conquered in non‐small cell lung cancer (NSCLC)
    Hanxiao Chen, Jun Zhao
    Thoracic Cancer.2020; 11(12): 3425.     CrossRef
  • Epidemiologic Features of NSCLC Gene Alterations in Hispanic Patients from Puerto Rico
    Ruifang Zheng, Zhiwei Yin, Albert Alhatem, Derek Lyle, Bei You, Andrew S. Jiang, Dongfang Liu, Zsolt Jobbagy, Qing Wang, Seena Aisner, Jie-Gen Jiang
    Cancers.2020; 12(12): 3492.     CrossRef
  • Comprehensive pancancer genomic analysis reveals (RTK)-RAS-RAF-MEK as a key dysregulated pathway in cancer: Its clinical implications
    Robin Imperial, Omer M Toor, Arif Hussain, Janakiraman Subramanian, Ashiq Masood
    Seminars in Cancer Biology.2019; 54: 14.     CrossRef
  • Epidermal growth factor receptor (EGFR), KRAS, and BRAF mutations in lung adenocarcinomas: A study from India
    Varsha Singh, Prerna Guleria, Prabhat Singh Malik, Anant Mohan, Sanjay Thulkar, R M Pandey, Kalpana Luthra, Sudheer Arava, Ruma Ray, Deepali Jain
    Current Problems in Cancer.2019; 43(5): 391.     CrossRef
  • Clinical Validation of Coexisting Activating Mutations Within EGFR, Mitogen-Activated Protein Kinase, and Phosphatidylinositol 3-Kinase Pathways in Lung Cancers
    Federico De Marchi, Lisa Haley, Henderson Fryer, Junaid Ibrahim, Katie Beierl, Gang Zheng, Christopher D. Gocke, James R. Eshleman, Deborah Belchis, Peter Illei, Ming-Tseh Lin
    Archives of Pathology & Laboratory Medicine.2019; 143(2): 174.     CrossRef
  • A sequential Monte Carlo algorithm for inference of subclonal structure in cancer
    Oyetunji E. Ogundijo, Kaiyi Zhu, Xiaodong Wang, Dimitris Anastassiou, Xiang Li
    PLOS ONE.2019; 14(1): e0211213.     CrossRef
  • The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients
    Anna Rachiglio, Francesca Fenizia, Maria Piccirillo, Domenico Galetta, Lucio Crinò, Bruno Vincenzi, Emiddio Barletta, Carmine Pinto, Francesco Ferraù, Matilde Lambiase, Agnese Montanino, Cristin Roma, Vienna Ludovini, Elisabetta Montagna, Antonella De Luc
    Cancers.2019; 11(3): 341.     CrossRef
  • Concurrent Driver Gene Mutations as Negative Predictive Factors in Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer
    Minjiang Chen, Yan Xu, Jing Zhao, Wei Zhong, Li Zhang, Yalan Bi, Mengzhao Wang
    EBioMedicine.2019; 42: 304.     CrossRef
  • Anaplastic Lymphoma Kinase (ALK)-positive Tumors
    Rohan Gupta, Idoroenyi Amanam, Syed Rahmanuddin, Isa Mambetsariev, Yingyu Wang, Charity Huang, Karen Reckamp, Lalit Vora, Ravi Salgia
    American Journal of Clinical Oncology.2019; 42(4): 337.     CrossRef
  • Clinical features and therapeutic options in non‐small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF
    Xibin Zhuang, Chao Zhao, Jiayu Li, Chunxia Su, Xiaoxia Chen, Shengxiang Ren, Xuefei Li, Caicun Zhou
    Cancer Medicine.2019; 8(6): 2858.     CrossRef
  • Intrinsic resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
    Santoni-Rugiu, Melchior, Urbanska, Jakobsen, Stricker, Grauslund, Sørensen
    Cancers.2019; 11(7): 923.     CrossRef
  • Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation
    J. Chantharasamee, N. Poungvarin, P. Danchaivijitr, S. Techawatanawanna
    BMC Cancer.2019;[Epub]     CrossRef
  • Deregulated lncRNA expression profile in the mouse lung adenocarcinomas with KRAS‐G12D mutation and P53 knockout
    Meiqin Zhang, Nan Jiang, Renjie Cui, Sichen Du, Huayuan Ou, Tinglan Chen, Runsheng Ge, Duan Ma, Jin Zhang
    Journal of Cellular and Molecular Medicine.2019; 23(10): 6978.     CrossRef
  • Open-Sourced CIViC Annotation Pipeline to Identify and Annotate Clinically Relevant Variants Using Single-Molecule Molecular Inversion Probes
    Erica K. Barnell, Adam Waalkes, Matt C. Mosior, Kelsi Penewit, Kelsy C. Cotto, Arpad M. Danos, Lana M. Sheta, Katie M. Campbell, Kilannin Krysiak, Damian Rieke, Nicholas C. Spies, Zachary L. Skidmore, Colin C. Pritchard, Todd A. Fehniger, Ravindra Uppalur
    JCO Clinical Cancer Informatics.2019; (3): 1.     CrossRef
  • EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma
    Maria Colombino, Panagiotis Paliogiannis, Antonio Cossu, Davide Adriano Santeufemia, Maria Cristina Sini, Milena Casula, Grazia Palomba, Antonella Manca, Marina Pisano, Valentina Doneddu, Giuseppe Palmieri
    BMC Pulmonary Medicine.2019;[Epub]     CrossRef
  • Concomitant Presence of EGFR and ALK Fusion Gene Mutation in Adenocarcinoma of Lung: A Case Report and Review of the Literature
    Nishitha Thumallapally, Hana Yu, Mohammad Farhan, Uroosa Ibrahim, Maricel Odiami
    Journal of Pharmacy Practice.2018; 31(2): 244.     CrossRef
  • Double Trouble: A Case Series on Concomitant Genetic Aberrations in NSCLC
    Nele Van Der Steen, Yves Mentens, Marc Ramael, Leticia G. Leon, Paul Germonpré, Jose Ferri, David R. Gandara, Elisa Giovannetti, Godefridus J. Peters, Patrick Pauwels, Christian Rolfo
    Clinical Lung Cancer.2018; 19(1): 35.     CrossRef
  • KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target
    Marta Román, Iosune Baraibar, Inés López, Ernest Nadal, Christian Rolfo, Silvestre Vicent, Ignacio Gil-Bazo
    Molecular Cancer.2018;[Epub]     CrossRef
  • Pulmonary Adenocarcinoma, Harboring Both an EGFR Mutation and ALK Rearrangement, Presenting a Stable Disease to Erlotinib and a Partial Response to Alectinib
    Akira Yokoyama, Atsuhisa Tamura, Kazuko Miyakawa, Kei Kusaka, Masahiro Shimada, Takashi Hirose, Hirotoshi Matsui, Masashi Kitani, Akira Hebisawa, Ken Ohta
    Internal Medicine.2018; 57(16): 2377.     CrossRef
  • Long-term survival with erlotinib in advanced lung adenocarcinoma harboring synchronous EGFR G719S and KRAS G12C mutations
    Biagio Ricciuti, Sara Baglivo, Vienna Ludovini, Angelo Sidoni, Giulio Metro, Marta Brambilla, Annamaria Siggillino, Maria Sole Reda, Alberto Rebonato, Daniele Maiettini, Rita Chiari
    Lung Cancer.2018; 120: 70.     CrossRef
  • Concomitant driver mutations in advanced EGFR-mutated non-small-cell lung cancer and their impact on erlotinib treatment
    Jan Nyrop Jakobsen, Eric Santoni-Rugiu, Morten Grauslund, Linea Melchior, Jens Benn Sørensen
    Oncotarget.2018; 9(40): 26195.     CrossRef
  • Implications of KRAS mutations in acquired resistance to treatment in NSCLC
    Marzia Del Re, Eleonora Rofi, Giuliana Restante, Stefania Crucitta, Elena Arrigoni, Stefano Fogli, Massimo Di Maio, Iacopo Petrini, Romano Danesi
    Oncotarget.2018; 9(5): 6630.     CrossRef
  • Alk Immunohistochemistry is Highly Sensitive and Specific for the Detection of Alk Translocated Lung Adenocarcinomas: Lessons from An Audit of Lung Cancer Molecular Testing
    YC Kheng, K Walsh, L Williams, WA Wallace, DJ Harrison, A Oniscu
    Journal of the Royal College of Physicians of Edinburgh.2018; 48(1): 20.     CrossRef
  • Targeting KRAS mutated non-small cell lung cancer: A history of failures and a future of hope for a diverse entity
    Alexios Matikas, Dimitrios Mistriotis, Vasilios Georgoulias, Athanasios Kotsakis
    Critical Reviews in Oncology/Hematology.2017; 110: 1.     CrossRef
  • Clinical Outcome of ALK -Positive Non–Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs)
    Sabine Schmid, Oliver Gautschi, Sacha Rothschild, Michael Mark, Patrizia Froesch, Dirk Klingbiel, Hermann Reichegger, Wolfram Jochum, Joachim Diebold, Martin Früh
    Journal of Thoracic Oncology.2017; 12(4): 681.     CrossRef
  • EGFR and KRAS molecular genotyping for pulmonary carcinomas: Feasibility of a simple and rapid technique implementable in any department of pathology
    Vincent Thomas De Montpréville, Maria-Rosa Ghigna, Ludovic Lacroix, Antoinette Lemoine, Benjamin Besse, Olaf Mercier, Élie Fadel, Peter Dorfmuller, Thierry Le Chevalier
    Pathology - Research and Practice.2017; 213(7): 793.     CrossRef
  • MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values
    Geun Dong Lee, Seung Eun Lee, Doo-Yi Oh, Dan-bi Yu, Hae Min Jeong, Jooseok Kim, Sungyoul Hong, Hun Soon Jung, Ensel Oh, Ji-Young Song, Mi-Sook Lee, Mingi Kim, Kyungsoo Jung, Jhingook Kim, Young Kee Shin, Yoon-La Choi, Hyeong Ryul Kim
    Journal of Thoracic Oncology.2017; 12(8): 1233.     CrossRef
  • Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02–14 Study)
    Jean-Bernard Auliac, Isabelle Monnet, Catherine Dubos-Arvis, Anne Marie Chiappa, Nathalie Baize, Suzana Bota, Alain Vergnenegre, Helene Doubre, Chrystele Locher, Acya Bizieux, Gilles Robinet, Christos Chouaid
    Targeted Oncology.2017; 12(6): 833.     CrossRef
  • Concomitant EML4-ALK rearrangement and EGFR mutation in non-small cell lung cancer patients: a literature review of 100 cases
    Giuseppe Lo Russo, Martina Imbimbo, Giulia Corrao, Claudia Proto, Diego Signorelli, Milena Vitali, Monica Ganzinelli, Laura Botta, Nicoletta Zilembo, Filippo de Braud, Marina Chiara Garassino
    Oncotarget.2017; 8(35): 59889.     CrossRef
  • Management of non-small cell lung cancer in the era of personalized medicine
    Gaetano Rocco, Alessandro Morabito, Alessandra Leone, Paolo Muto, Francesco Fiore, Alfredo Budillon
    The International Journal of Biochemistry & Cell Biology.2016; 78: 173.     CrossRef
  • A long-term survivor of non-small-cell lung cancer harboring concomitant EGFR mutation and ALK translocation
    Fumio Imamura, Takako Inoue, Madoka Kimura, Kazumi Nishino, Toru Kumagai
    Respiratory Medicine Case Reports.2016; 19: 137.     CrossRef
Brief Case Report
A Rare Case of Pulmonary Arteriovenous Hemangioma Presenting as a Peribronchial Mass
Soomin Ahn, Sejin Jung, Jong Ho Cho, Tae Sung Kim, Joungho Han
J Pathol Transl Med. 2016;50(3):243-245.   Published online November 17, 2015
DOI: https://doi.org/10.4132/jptm.2015.10.15
  • 7,616 View
  • 57 Download
  • 2 Crossref
PDF

Citations

Citations to this article as recorded by  
  • Incidental discovery of a large complicated arteriovenous haemangioma
    Alberto Anthony Goizueta, Peter Libbey, Anthony Moulton, Rabih El-Bizri
    BMJ Case Reports.2017; : bcr-2016-218759.     CrossRef
  • Pulmonary Arteriovenous Fistula: Clinical and Histologic Spectrum of Four Cases
    Soomin Ahn, Joungho Han, Hong Kwan Kim, Tae Sung Kim
    Journal of Pathology and Translational Medicine.2016; 50(5): 390.     CrossRef
Original Article
Comprehensive Cytomorphologic Analysis of Pulmonary Adenoid Cystic Carcinoma: Comparison to Small Cell Carcinoma and Non-pulmonary Adenoid Cystic Carcinoma
Seokhwi Kim, Jinah Chu, Hojoong Kim, Joungho Han
J Pathol Transl Med. 2015;49(6):511-519.   Published online October 19, 2015
DOI: https://doi.org/10.4132/jptm.2015.09.07
  • 8,957 View
  • 61 Download
  • 5 Web of Science
  • 5 Crossref
AbstractAbstract PDF
Background
Cytologic diagnosis of pulmonary adenoid cystic carcinoma (AdCC) is frequently challenging and differential diagnosis with small cell carcinoma is often difficult. Methods: Eleven cytologically diagnosed cases of pulmonary AdCC were collected and reviewed according to fifteen cytomorphologic characteristics: small cell size, cellular uniformity, coarse chromatin, hyperchromasia, distinct nucleolus, frequent nuclear molding, granular cytoplasm, organoid cluster, sheet formation, irregular border of cluster, hyaline globule, hyaline basement membrane material, individual cell necrosis or apoptotic body, and necrotic background. Twenty cases of small cell carcinoma and fifteen cases of non-pulmonary AdCC were also reviewed for the comparison. Results: Statistically significant differences were identified between pulmonary AdCC and small cell carcinoma in fourteen of the fifteen cytomorphologic criteria (differences in sheet formation were not statistically significant). Cellular uniformity, distinct nucleolus, granular cytoplasm, distinct cell border, organoid cluster, hyaline globule, and hyaline basement membrane material were characteristic features of AdCC. Frequent nuclear molding, individual cell necrosis, and necrotic background were almost exclusively identified in small cell carcinoma. Although coarse chromatin and irregular cluster border were observed in both, they favored the diagnosis of small cell carcinoma. Hyaline globules were more frequently seen in non-pulmonary AdCC cases. Conclusions: Using the fifteen cytomorphologic criteria described by this study, pulmonary AdCC could be successfully distinguished from small cell carcinoma. Such a comprehensive approach to an individual case is recommended for the cytologic diagnosis of pulmonary AdCC.

Citations

Citations to this article as recorded by  
  • Recent developments in the pathology of primary pulmonary salivary gland‐type tumours
    Julia R Naso, Anja C Roden
    Histopathology.2024; 84(1): 102.     CrossRef
  • Bronchial cytology of pulmonary adenoid cystic carcinoma – A multi-institute series with emphasis on immunocytochemistry
    Joanna K.M. Ng, Ka Pang Chan, Gary M. Tse, Joshua J.X. Li
    Annals of Diagnostic Pathology.2023; 64: 152132.     CrossRef
  • Pulmonary adenoid cystic carcinoma: molecular characteristics and literature review
    Zhixin Chen, Jiapeng Jiang, Ying Fan, Hongyang Lu
    Diagnostic Pathology.2023;[Epub]     CrossRef
  • Recent updates in salivary gland tumors of the lung
    Anja C. Roden
    Seminars in Diagnostic Pathology.2021; 38(5): 98.     CrossRef
  • Cytology of Primary Salivary Gland-Type Tumors of the Lower Respiratory Tract: Report of 15 Cases and Review of the Literature
    Chiara Saglietti, Marco Volante, Stefano La Rosa, Igor Letovanec, Marc Pusztaszeri, Gaia Gatti, Massimo Bongiovanni
    Frontiers in Medicine.2017;[Epub]     CrossRef
Brief Case Report
A Rare Case of Thymic Gangliocytic Paraganglioma
Jung Wook Yang, Joungho Han, Hyun Woo Lee, Soo Youn Cho, Hong Kwan Kim
J Pathol Transl Med. 2016;50(2):165-167.   Published online October 8, 2015
DOI: https://doi.org/10.4132/jptm.2015.07.15
  • 7,544 View
  • 51 Download
  • 5 Web of Science
  • 7 Crossref
PDF

Citations

Citations to this article as recorded by  
  • Primary gangliocytic paraganglioma of the lung
    Yee Sing Lin, Christopher Cao, Wendy A. Cooper, Veronica Ka-Yan Cheung
    Pathology.2024; 56(3): 423.     CrossRef
  • Pulmonary gangliocytic paraganglioma: An under-recognized mimic of carcinoid tumor
    Julia R. Naso, Diping Wang, Arthur O. Romero, Timothy Leclair, Peter Smit, Jennifer M. Boland, Andrew L. Folpe, Melanie C. Bois
    Human Pathology.2024; 146: 23.     CrossRef
  • Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas
    Ozgur Mete, Sylvia L. Asa, Anthony J. Gill, Noriko Kimura, Ronald R. de Krijger, Arthur Tischler
    Endocrine Pathology.2022; 33(1): 90.     CrossRef
  • The Rarest of Rare Thymic Lesions: A 10-Year Surgical Pathology Experience
    Fiorella Calabrese, Francesco Fortarezza, Federica Pezzuto, Francesca Lunardi, Giovanni Comacchio, Marta Sbaraglia, Giulia Pasello, Giuseppe Marulli, Angelo Paolo Dei Tos, Federico Rea
    Cancers.2021; 13(16): 4056.     CrossRef
  • Gangliocytic Paraganglioma of the Minor Papilla of the Duodenum
    Hiroyuki Matsubayashi, Hirotoshi Ishiwatari, Toru Matsui, Shinya Fujie, Katsuhiko Uesaka, Teiichi Sugiura, Yukiyasu Okamura, Yusuke Yamamoto, Ryo Ashida, Takaaki Ito, Keiko Sasaki, Hiroyuki Ono
    Internal Medicine.2017; 56(9): 1029.     CrossRef
  • Endoscopic resection of a periampullary gangliocytic paraganglioma of the duodenum: A case report
    Christoph Paasch, Michael Hünerbein, Franz Theissig
    International Journal of Surgery Case Reports.2016; 29: 39.     CrossRef
  • Duodenal Rare Neuroendocrine Tumor: Clinicopathological Characteristics of Patients with Gangliocytic Paraganglioma
    Yoichiro Okubo, Tomoyuki Yokose, Osamu Motohashi, Yohei Miyagi, Emi Yoshioka, Masaki Suzuki, Kota Washimi, Kae Kawachi, Madoka Nito, Tetsuo Nemoto, Kazutoshi Shibuya, Yoichi Kameda
    Gastroenterology Research and Practice.2016; 2016: 1.     CrossRef
Original Article
Analysis of Histologic Features Suspecting Anaplastic Lymphoma Kinase (ALK)-Expressing Pulmonary Adenocarcinoma
In Ho Choi, Dong Won Kim, Sang Yun Ha, Yoon-La Choi, Hee Jeong Lee, Joungho Han
J Pathol Transl Med. 2015;49(4):310-317.   Published online June 22, 2015
DOI: https://doi.org/10.4132/jptm.2015.05.13
  • 9,418 View
  • 86 Download
  • 18 Web of Science
  • 19 Crossref
AbstractAbstract PDF
Background
Since 2007 when anaplastic lymphoma kinase (ALK) rearrangements were discovered in non-small cell lung cancer, the ALK gene has received attention due to ALK-targeted therapy, and a notable treatment advantage has been observed in patients harboring the EML4/ALK translocation. However, using ALK-fluorescence in situ hybridization (FISH) as the standard method has demerits such as high cost, a time-consuming process, dependency on interpretation skill, and tissue preparation. We analyzed the histologic findings which could complement the limitation of ALK-FISH test for pulmonary adenocarcinoma. Methods: Two hundred five cases of ALK-positive and 101 of ALK-negative pulmonary adenocarcinoma from January 2007 to May 2013 were enrolled in this study. The histologic findings and ALK immunohistochemistry results were reviewed and compared with the results of ALK-FISH and EGFR/KRAS mutation status. Results: Acinar, cribriform, and solid growth patterns, extracellular and intracellular mucin production, and presence of signet-ring-cell element, and psammoma body were significantly more often present in ALK-positive cancer. In addition, the presence of goblet cell-like cells and presence of nuclear inclusion and groove resembling papillary thyroid carcinoma were common in the ALK-positive group. Conclusions: The above histologic parameters can be helpful in predicting ALK rearranged pulmonary adenocarcinoma, leading to rapid FISH analysis and timely treatment.

Citations

Citations to this article as recorded by  
  • Clinicopathological significances of cribriform pattern in lung adenocarcinoma
    Jung-Soo Pyo, Byoung-Hoon Lee, Kyueng-Whan Min, Nae Yu Kim
    Pathology - Research and Practice.2024; 253: 155035.     CrossRef
  • Clinicopathological features and prognostic significance of pulmonary adenocarcinoma with signet ring cell components: meta-analysis and SEER analysis
    Yang Tan, Ying-he Huang, Jia-wen Xue, Rui Zhang, Run Liu, Yan Wang, Zhen-Bo Feng
    Clinical and Experimental Medicine.2023; 23(8): 4341.     CrossRef
  • Lung-Cancer Risk in Mice after Exposure to Gamma Rays, Carbon Ions or Neutrons: Egfr Pathway Activation and Frequent Nuclear Abnormality
    Kenshi Suzuki, Shunsuke Yamazaki, Ken-ichi Iwata, Yutaka Yamada, Takamitsu Morioka, Kazuhiro Daino, Mutsumi Kaminishi, Mari Ogawa, Yoshiya Shimada, Shizuko Kakinuma
    Radiation Research.2022;[Epub]     CrossRef
  • Pathological cytomorphologic features and the percentage of ALK FISH-positive cells predict pulmonary adenocarcinoma prognosis: a prospective cohort study
    Fenge Jiang, Congcong Wang, Ping Yang, Ping Sun, Jiannan Liu
    World Journal of Surgical Oncology.2021;[Epub]     CrossRef
  • Cribriform pattern in lung invasive adenocarcinoma correlates with poor prognosis in a Chinese cohort
    Yang Qu, Haifeng Lin, Chen Zhang, Kun Li, Haiqing Zhang
    Pathology - Research and Practice.2019; 215(2): 347.     CrossRef
  • Incidence of brain metastasis in lung adenocarcinoma at initial diagnosis on the basis of stage and genetic alterations
    Bumhee Yang, Hyun Lee, Sang-Won Um, Kyunga Kim, Jae Il Zo, Young Mog Shim, O Jung Kwon, Kyung Soo Lee, Myung-Ju Ahn, Hojoong Kim
    Lung Cancer.2019; 129: 28.     CrossRef
  • Qualitative and quantitative cytomorphological features of primary anaplastic lymphoma kinase‐positive lung cancer
    Ryuko Tsukamoto, Hiroyuki Ohsaki, Sho Hosokawa, Yasunori Tokuhara, Shingo Kamoshida, Toshiko Sakuma, Tomoo Itoh, Chiho Ohbayashi
    Cytopathology.2019; 30(3): 295.     CrossRef
  • Double Trouble: A Case Series on Concomitant Genetic Aberrations in NSCLC
    Nele Van Der Steen, Yves Mentens, Marc Ramael, Leticia G. Leon, Paul Germonpré, Jose Ferri, David R. Gandara, Elisa Giovannetti, Godefridus J. Peters, Patrick Pauwels, Christian Rolfo
    Clinical Lung Cancer.2018; 19(1): 35.     CrossRef
  • Update on the potential significance of psammoma bodies in lung adenocarcinoma from a modern perspective
    Akio Miyake, Koji Okudela, Mai Matsumura, Mitsui Hideaki, Hiromasa Arai, Shigeaki Umeda, Shoji Yamanaka, Yoshihiro Ishikawa, Michihiko Tajiri, Kenichi Ohashi
    Histopathology.2018; 72(4): 609.     CrossRef
  • Integrin β3 Inhibition Enhances the Antitumor Activity of ALK Inhibitor in ALK-Rearranged NSCLC
    Ka-Won Noh, Insuk Sohn, Ji-Young Song, Hyun-Tae Shin, Yu-Jin Kim, Kyungsoo Jung, Minjung Sung, Mingi Kim, Sungbin An, Joungho Han, Se-Hoon Lee, Mi-Sook Lee, Yoon-La Choi
    Clinical Cancer Research.2018; 24(17): 4162.     CrossRef
  • An anaplastic lymphoma kinase-positive lung cancer microlesion: A case report
    Tetsuo Kon, Youichiro Baba, Ichiro Fukai, Gen Watanabe, Tomoko Uchiyama, Tetsuya Murata
    Human Pathology: Case Reports.2017; 7: 11.     CrossRef
  • The prevalence of ALK rearrangement in pulmonary adenocarcinomas in an unselected Caucasian population from a defined catchment area: impact of smoking
    Birgit G Skov, Paul Clementsen, Klaus R Larsen, Jens B Sørensen, Anders Mellemgaard
    Histopathology.2017; 70(6): 889.     CrossRef
  • Ciliated muconodular papillary tumor of the lung harboring ALK gene rearrangement: Case report and review of the literature
    Yan Jin, Xuxia Shen, Lei Shen, Yihua Sun, Haiquan Chen, Yuan Li
    Pathology International.2017; 67(3): 171.     CrossRef
  • Molecular breakdown: a comprehensive view of anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
    Ka‐Won Noh, Mi‐Sook Lee, Seung Eun Lee, Ji‐Young Song, Hyun‐Tae Shin, Yu Jin Kim, Doo Yi Oh, Kyungsoo Jung, Minjung Sung, Mingi Kim, Sungbin An, Joungho Han, Young Mog Shim, Jae Ill Zo, Jhingook Kim, Woong‐Yang Park, Se‐Hoon Lee, Yoon‐La Choi
    The Journal of Pathology.2017; 243(3): 307.     CrossRef
  • Anaplastic lymphoma kinase immunohistochemistry in lung adenocarcinomas: Evaluation of performance of standard manual method using D5F3 antibody
    D Jain, K Jangra, PS Malik, S Arulselvi, K Madan, S Mathur, MC Sharma
    Indian Journal of Cancer.2017; 54(1): 209.     CrossRef
  • Clinicopathological Features and Therapeutic Responses of Chinese Patients with Advanced Lung Adenocarcinoma Harboring an Anaplastic Lymphoma Kinase Rearrangement
    Danxia Lin, De Zeng, Chen Chen, Xiao Wu, Miaojun Wang, Jiongyu Chen, Hui Lin, Xihui Qiu
    Oncology Research and Treatment.2017; 40(1-2): 27.     CrossRef
  • A Validation Study for the Use of ROS1 Immunohistochemical Staining in Screening for ROS1 Translocations in Lung Cancer
    Patrizia Viola, Manisha Maurya, James Croud, Jana Gazdova, Nadia Suleman, Eric Lim, Tom Newsom-Davis, Nick Plowman, Alexandra Rice, M. Angeles Montero, David Gonzalez de Castro, Sanjay Popat, Andrew G. Nicholson
    Journal of Thoracic Oncology.2016; 11(7): 1029.     CrossRef
  • Non-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases
    Taebum Lee, Boram Lee, Yoon-La Choi, Joungho Han, Myung-Ju Ahn, Sang-Won Um
    Journal of Pathology and Translational Medicine.2016; 50(3): 197.     CrossRef
  • ALK gene rearranged lung adenocarcinomas: molecular genetics and morphology in cohort of patients from North India
    Amanjit Bal, Navneet Singh, Parimal Agarwal, Ashim Das, Digambar Behera
    APMIS.2016; 124(10): 832.     CrossRef
Brief Case Reports
A Rare Case of Tumor-to-Tumor Metastasis of Thyroid Papillary Carcinoma within a Pulmonary Adenocarcinoma
Taebum Lee, Yoon Jin Cha, Sangjeong Ahn, Joungho Han, Young Mog Shim
J Pathol Transl Med. 2015;49(1):78-80.   Published online January 15, 2015
DOI: https://doi.org/10.4132/jptm.2014.12.15
  • 8,177 View
  • 55 Download
  • 7 Web of Science
  • 9 Crossref
PDF

Citations

Citations to this article as recorded by  
  • Metástasis tumor a tumor en pulmón: reporte de tres casos y revisión de la literatura
    Paula Cristina Castro Quiroga, Blanca Viviana Fajardo Idrobo, Diana Marcela Caicedo Ruiz, Julieth Alexandra Franco Mira, Carlos Andrés Carvajal Fierro, Alfredo Ernesto Romero Rojas, Rafael Santiago Parra Medina
    Revista Colombiana de Cancerología.2023; 27(1): 107.     CrossRef
  • Benign Neurofibroma/Schwannoma Hybrid Peripheral Nerve Sheath Tumor of the Ulnar Nerve Harboring a Metastatic Papillary Thyroid Carcinoma Deposit: A Case Report of Tumor-to-Tumor Metastasis
    Juan M. Colazo, Alexander N. Perez, Anthony D. Judice, Julia Quirion, Carlos N. Prieto-Granada, Ginger E. Holt, Samir Sami Amr
    Case Reports in Pathology.2022; 2022: 1.     CrossRef
  • A case of colorectal cancer with intratumoral metastasis to primary lung cancer
    Yasushi Cho, Mitsuhito Kaji, Shunsuke Nomura, Yusuke Motohashi, Masaaki Sato, Motoya Takeuchi
    The Journal of the Japanese Association for Chest Surgery.2021; 35(5): 576.     CrossRef
  • Tumor-to-tumor metastasis: metastatic invasive lobular carcinoma of the breast within adenocarcinoma of the lung
    Myoung Jae Kang, Ae Ri An, Myoung Ja Chung, Kyoung Min Kim
    Journal of Pathology and Translational Medicine.2020; 54(2): 188.     CrossRef
  • Metastatic Renal Cell Neoplasm Within a Papillary Thyroid Carcinoma as Incidental Finding in an Asymptomatic Patient: a Case Report
    Maria-Rosa Bella-Cueto, Mireia Pascua-Solé, Albert Cano-Palomares, M. Àngels Cabezuelo-Hernandez, Maria-Rosa Escoda-Giralt, Santiago Barcons-Vilaplana, Paula Serret-Miralles, Carmen Caral-Vanaclocha, Xavier Guirao-Garriga, Joan Prats-Lopez, Meritxell Meda
    SN Comprehensive Clinical Medicine.2020; 2(7): 978.     CrossRef
  • Squamous cell carcinoma of the lung and pulmonary metastasis of papillary thyroid carcinoma: a case report
    Arya Aminorroaya, Mohsen Khoshniatnikoo, Hossein Farrokhpour, Jamshid Vafaeimanesh, Mohammad Bagherzadeh
    Journal of Medical Case Reports.2019;[Epub]     CrossRef
  • Prostatic adenocarcinoma (PCa) metastasizing to renal cell carcinoma (RCC) with periureteral tumor deposit: A case of tumor-to-tumor metastasis (TTM)
    Jenissa Amor Dionisio Arceño, Jonathan Salcedo Mendoza, Josefino Cortez Castillo, Jeffrey Santos So
    Human Pathology: Case Reports.2017; 8: 27.     CrossRef
  • Dual malignancy in a thyroid; papillary thyroid carcinoma and small lymphocytic lymphoma; a report of a case with a cyto‐histologic correlation
    Omar I. Ahmed, Ziyan T. Salih
    Diagnostic Cytopathology.2017; 45(9): 851.     CrossRef
  • Reactivity of thyroid papillary carcinoma cells to thyroid stimulating hormone-dominated endocrine therapy
    Yuqin Ma, Xia Zhang, Yutao Wang
    Oncology Letters.2017;[Epub]     CrossRef
A Rare Case of Mixed Type A Thymoma and Micronodular Thymoma with Lymphoid Stroma
Yoon Jin Cha, Joungho Han, Jimin Kim, Kyung Soo Lee, Young Mog Shim
J Pathol Transl Med. 2015;49(1):75-77.   Published online January 15, 2015
DOI: https://doi.org/10.4132/jptm.2014.10.27
  • 9,749 View
  • 84 Download
  • 9 Web of Science
  • 9 Crossref
PDF

Citations

Citations to this article as recorded by  
  • GTF2Imutation in micronodular thymoma with lymphoid stroma
    Andrea Bille, Katherine Fryer, Andrew Wallace, Daisuke Nonaka
    Journal of Clinical Pathology.2024; 77(2): 125.     CrossRef
  • Constant p.L424H Mutation in GTF2I in Micronodular Thymomas With Lymphoid Stroma: Evidence Supporting Close Relationship With Type A and AB Thymomas
    Min-Shu Hsieh, Hua-Lin Kao, Wen-Chang Huang, Shu-Ying Wang, Shin-Ying Lin, Ping-Yuan Chu, Chin-Chen Pan, Teh-Ying Chou, Hsiang-Ling Ho, Yi-Chen Yeh
    Modern Pathology.2023; 36(2): 100008.     CrossRef
  • Comparative clinicopathological and immunohistochemical study of micronodular thymoma and micronodular thymic carcinoma with lymphoid stroma
    Ping Ping Liu, Yun Chao Su, Yun Niu, Yan Fen Shi, Jie Luo, Ding Rong Zhong
    Journal of Clinical Pathology.2022; 75(10): 702.     CrossRef
  • Micronodular Thymoma With Lymphoid Stroma: A Trio of Cases, With Diverse-associated Histological Features
    Neha Bakshi, Shashi Dhawan, Seema Rao, Kishan Singh Rawat
    International Journal of Surgical Pathology.2021; 29(6): 693.     CrossRef
  • A case of thymoma with type A and micronodular thymoma with lymphoid stroma elements
    Clayton E. Kibler, Matthew J. Cecchini, Marie-Christine Aubry, Said F. Yassin, Julie K. Harrington
    Human Pathology: Case Reports.2021; 23: 200487.     CrossRef
  • Micronodular thymoma with lymphoid stroma: a clinicopathological study of five cases
    Katherine R. Hulme, Annabelle Mahar, Christopher Cao, Brian McCaughan, Wendy A. Cooper
    Pathology.2021; 53(7): 930.     CrossRef
  • Mixed Type A Thymoma and Micronodular Thymoma With Lymphoid Stroma
    Renqing Wang, Ling Nie
    International Journal of Surgical Pathology.2018; 26(4): 336.     CrossRef
  • Cystic Micronodular Thymoma. Report of a Case
    Mlika M
    Journal of Clinical, Medical and Experimental Images.2017; 1(1): 001.     CrossRef
  • Two Invasive Thymomas Incidentally Found during Coronary Artery Bypass Graft Surgery
    Navid Omidifar, Maral Mokhtari, Mansoureh Shokripour
    Case Reports in Pathology.2016; 2016: 1.     CrossRef

J Pathol Transl Med : Journal of Pathology and Translational Medicine